Back to top

Press Releases

Zacks Equity Research

NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

NVDA BID REGN CELG SNY

Trades from $3

For Immediate Release

Chicago, IL – November 30, 2016 – Zacks Equity Research highlights NVIDIA (NASDAQ:(NVDA - Free Report) – Free Report) as the Bull of the Day and Sotheby's Holdings (NYSE:(BID - Free Report) – Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Celgene Corporation (NASDAQ:(CELG - Free Report) –Free Report),Regeneron Pharmaceuticals, Inc. (NASDAQ:(REGN - Free Report) –Free Report) and Sanofi (NYSE:(SNY - Free Report) – Free Report).

Here is a synopsis of all five stocks:

Bull of the Day:

I last wrote about NVIDIA (NASDAQ:(NVDA - Free Report) – Free Report) as the Bull of the Day in mid-August when you could still scoop shares near $60. Before that, I was recommending shares under $30 in January when its emerging earnings momentum made it a compelling combination of growth and value in technology.

Since then, the specialty semiconductor graphics company delivered another blowout quarter of results that have driven shares above $90, and reinstalled the stock as a fixture in the top tier of the Zacks Rank as a #1 Strong Buy.

Earnings Stunner

On November 10, NVIDIA reported record quarterly revenue of $2 billion, up 54% from a year ago, and up 40% from $1.43 billion in the previous quarter.

The company also delivered record GAAP EPS of $0.83, up 89 percent from a year ago. This was over 45% better than the Zacks/Wall Street consensus.

In response to these results and optimistic company guidance, analysts scrambled to raise estimates yet again. Full-year EPS projections for the current fiscal year ending in January 2017 rose 33% from $1.86 to $2.48.

And next year's consensus profit estimate surged 43.5% from $1.93 to $2.77. And even after a fantastic year where NVIDIA is projected to hit $6.84 billion on the top line for 36%+ sales growth, next year's consensus is for 14.5% revenue growth to $7.84.

Firing on All Frontiers

NVIDIA designs, develops and markets a top-to-bottom family of award-winning 3D graphics processors, graphics processing units and related software that set the standard for performance, quality and features for every type of desktop personal computer user, from professional workstations to low-cost computers.

NVIDIA's 3D graphics processors are well known in the video game industry, but the company has been steadily making inroads into virtual reality, education applications and machine learning technology like that for autonomous driving.

Here's what the founder and CEO had to say about their growth...

"We had a breakout quarter - record revenue, record margins and record earnings were driven by strength across all product lines," said Jen-Hsun Huang, founder and chief executive officer, NVIDIA. "Our new Pascal GPUs are fully ramped and enjoying great success in gaming, VR, self-driving cars and datacenter AI computing…”

Bear of the Day :

There is a reason that esteemed fine arts auction house Sotheby's Holdings (NYSE:(BID - Free Report) – Free Report) shares have gone sideways for five years, still stuck under $40 like they were in 2012.

That reason is earnings, or the lack of earnings growth I should say. Thus the stock has spent considerable time in and out of the Zacks #5 Rank cellar as earnings estimates start out the year overly-optimistic, only to be brought back down to earth.

And this is probably the third time I have chosen to write about BID as the Bear of the Day.

The most recent analyst estimate revisions that hit Sotheby's followed their big Q3 earnings miss earlier this month. Analysts quickly took down this year's full-year consensus 30% from $2.24 to $1.57, representing -24% EPS growth.

This disappointment followed a surprisingly good Q2 when the company reported a 45% EPS beat in August. Clearly, the lumpiness in the business continues to haunt long-term investors, like activist Dan Loeb of Third Point Capital.

Additional content:

Celgene vs. Regeneron: Which Is the Better Stock?

It sure has been a tough year for biotech stocks but all that seems to have changed with the election results. Companies likeCelgene Corporation (NASDAQ:(CELG - Free Report) –Free Report) andRegeneron Pharmaceuticals, Inc. (NASDAQ:(REGN - Free Report) – Free Report), two key players in the industry, have seen a surge in their share prices post-election and look well-placed to enjoy a good run.

With both being Zacks Rank #2 (Buy) stocks, which one is a better choice for investors? Here is a look at a few factors that may help in making a choice.

Recent Earnings Performance

Celgene’s third quarter results were better-than-expected with the company beating both top- and bottom-line estimates. The company, which has a major presence in the cancer and immunology markets, benefited from the strong performance of its core products with growth being driven primarily by volume.

While blood cancer treatment, Revlimid, is the key contributor to the top-line and continues to deliver impressive growth, Celgene has been diversifying its portfolio with other drugs like Pomalyst and Otezla performing well too. Otezla (psoriasis, active psoriatic arthritis) has immense potential with sales being driven by demand, growing market share and an expanding global footprint. The product is comfortably on track to achieve blockbuster status in 2016.

Meanwhile, Regeneron topped earnings estimates though it missed on revenues. The company’s flagship product, eye treatment Eylea, continues to be the key financial driver. However, PCSK9 inhibitor, Praluent, is yet to show a significant ramp up in sales with scrips continuing to be impacted by reimbursement hurdles for physician offices and patients.

Guidance

Based on its performance, Celgene updated its 2016 outlook again. Continued momentum of core products should help the company achieve its raised outlook for 2016 as well as 2017.

Regeneron tightened its U.S. net product sales guidance range for Eylea to 23% - 25% growth over 2015 (old guidance: 20% - 25% growth). Eylea growth is expected to be driven by factors like demographics, an aging population and a higher number of patients with diabetic eye disease.

Pipeline Matters

For any pharma or biotech company, the pipeline is of utmost importance and plays an important role in investment decisions. So, it always makes sense to take a look at a company’s pipeline and upcoming catalysts.

Celgene has a rich and promising pipeline. In addition to working on expanding the labels of currently marketed products like Revlimid and Otezla, the company has phase III studies underway for ozanimod (ulcerative colitis and relapsing multiple sclerosis) and GED-0301 (Crohn’s disease) in the inflammation and immunology therapeutic area and for CC-486 (myelodysplastic syndromes and acute myeloid leukemia), enasidenib (acute myeloid leukemia) and luspatercept (myelodysplastic syndromes and beta-thalassemia) within hematology. What makes the pipeline more attractive is that some of these candidates have blockbuster potential.

Upcoming catalysts include a regulatory response in the U.S. (expected on Feb 24, 2017) and EU (first half of 2017) regarding the label expansion of Revlimid as maintenance treatment in newly diagnosed multiple myeloma patients after an autologous stem-cell transplant. Celgene also intends to seek FDA approval for enasidenib in relapsed and/or refractory acute myeloid leukemia with IDH2 mutation by year-end.

Regeneron has also been working on its pipeline and has sixteen product candidates in development including label expansion efforts for Eylea. But the company faced a few pipeline-related setbacks recently. Regeneron and its partner Sanofi (NYSE:(SNY - Free Report) – Free Report) got a complete response letter from the FDA in late October for sarilumab (an IL-6R antibody for rheumatoid arthritis) due to manufacturing issues at a Sanofi plant.

Regeneron suffered another setback in October with a phase IIb study on fasinumab, an investigational nerve growth factor (NGF) antibody, in patients with chronic low back pain being placed on clinical hold.

A key catalyst for Regeneron would be the FDA approval of Dupixent, currently under priority review for atopic dermatitis with a response expected on Mar 29, 2017. Dupixent is being investigated for other indications as well including asthma, nasal polyps, and eosinophilic esophagitis. Another major catalyst would be positive cardiovascular outcomes data on Praluent as this would help boost sales significantly.

Regeneron is also looking to grow its ophthalmology segment and is evaluating Eylea in combination with other treatments.

Price and Valuation Perspective

A look at Celgene’s year-to-date (YTD) price performance shows that although the company has witnessed ups and downs over the course of the year, overall it has outperformed the Zacks categorized Medical/Biomedical Genetics industry. Towards the beginning of the year, Celgene’s shares had dropped after the company released preliminary fourth-quarter 2015 and full-year results and guidance for 2016 which fell short of expectations. However, better-than-expected second quarter results and a raised outlook helped the shares rally. Like other biotech stocks, Celgene saw a significant surge in its share price following the election results reflecting investor relief at a non-Clinton presidency.

Meanwhile, a look at Regeneron’s chart shows that the company has underperformed the Zacks categorized Medical/Biomedical Genetics industry. Regeneron is one of the companies that had been under pressure due to the pre-election political rhetoric on rising drug prices. The company’s shares declined in February on disappointing fourth quarter results and guidance. Shares bounced back on first quarter results and a raised outlook for Eylea though the stock remained under pressure until the run up to the Presidential election. Shares shot up 13.8% immediately after election results were announced.

Based on current levels, Celgene is trading at a price earnings (P/E) multiple of 22.97 while Regeneron’s P/E multiple of 46.03 is much higher. Celgene looks cheaper from a PEG perspective as well given its PEG ratio of 1.07 compared to Regeneron’s PEG ratio of 2.12.

Bottom Line

Right now, Celgene looks like the better pick – the company has a lot going for it including a strong earnings track record, robust performance of core products, a diverse revenue stream, a rich pipeline with potential blockbuster candidates and an attractive valuation. As mentioned earlier, Celgene is a Zacks Rank #2 stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

Confidential: Zacks' Best Investment Ideas

Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. Click for his selected trades right now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Get today’s Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on NVDA - FREE

Get the full Report on BID - FREE

Get the full Report on CELG - FREE

Get the full Report on REGN - FREE

Get the full Report on SNY - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer .

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.